Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice

Journal of Molecular Endocrinology

Volumn 39, Issue 1-2, 2007, Pages 9-16

  Devin, Jessica K ^a   Johnson, Joyce E ^a   Eren, Mesut ^a   Gleaves, Linda A ^a   Bradham, William S ^a   Bloodworth Jr , John R ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY CYST; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ENDOTHELIN-1; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; OVARY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; TESTOSTERONE;

EID: 34548319286     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-06-0057     Document Type: Article

References (37)

1. Adams JM, Taylor AE, Crowley WF Jr & Hall JE 2004 Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 89 4343-4350.
2. Apridonidze T, Essah PA, Iuorno MJ & Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 90 1929-1935.
3. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH & Prentice AG 1998 The plasminogen activator system in women with polycystic ovary syndrome. Fertility and Sterility 69 236-241.
4. Berkenpas MB, Lawrence DA & Ginsburg D 1995 Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO Journal 14 2969-2977.
5. Chang RJ & Katz SE 1999 Diagnosis of polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America 28 397-408 (vii).
6. Dahlgren E, Janson PO, Johansson S, Lapidus L & Oden A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet7icia et Gynecologica Scandinavica 71 599-604.
7. Diamanti-Kandarakis E & Piperi C 2005 Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update 11 631-643.
8. Diamanti-Kandarakis E, Palioniko G, Alexandraki E, Bergiele A, Koutsouba T & Bartzis M 2004 The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. European Journal of Endocrinology 150 793-798.
9. Eren M, Painter CA, Atkinson JB, Declerck PJ & Vaughan DE 2002 Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106 491-496.
10. Festa A, D'Agostino RJr, Tracy RP & Haffner SM 2002 Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 1131-1137.
11. Festa A, Williams K, Tracy RP, Wagenknecht LE & Haffner SM 2006 Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113 1753-1759.
12. Glueck CJ, Sieve L, Zhu B & Wang P 2006 Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 55 345-352.
13. Hagglund AC, Ny A, Liu K & Ny T 1996 Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation. Endocrinology 137 5671-5677.
14. Harats D, Kurihara H, Belloni P, Oakley H, Ziober A, Ackley D, Cain G, Kurihara Y, Lawn R & Sigal E 1995 Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. Journal of Clinical Investigation 95 1335-1344.
15. Hughesdon PE 1982 Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called 'hyperthecosis'. Obstetrical and Gynecological Survey 37 59-77.
16. Jonard S & Dewailly D 2004 The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, maybe the main culprit for the follicular arrest. Human Reproduction Update 10 107-117.
17. Kero JT, Savontaus E, Mikola M, Pesonen U, Koulu M, Keri RA, Nilson JH, Poutanen M & Huhtaniemi IT 2003 Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. American Journal of Physiology. Endocrinology and Metabolism 285 E812-E818.
18. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A & Michalis LK 2005 Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 90 5088-5095.
19. Kyei-Mensah AA, LinTan S, Zaidi J & Jacobs HS 1998 Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Human Reproduction 13 1437-1441.
20. Legro RS, Castracane VD & Kauffman RP 2004 Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical and Gynecological Survey 59 141-154.
21. Lijnen HR 2005 Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis 3 35-45.
22. Liu YX 2004 Plasminogen activator/plasminogen activator inhibitors in ovarian physiology. Frontiers in Bioscience 9 3356-3373.
23. Liu Y, Brandstrom A, Liu YX, Ny T & Selstarn G 1996 Coordinated expression of tissue-type plasminogen activator and plasminogen activator inhibitor type I during corpus luteum formation and luteolysis in the adult pseudopregnant rat. Endocrinology 137 2126-2132.
24. Liu K, Liu YX, Hu ZY, Zou RY, Chen YJ, Mu XM & Ny T 1997 Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. Molecular and Cellular Endocrinology 133 109-116.
25. Liu YX, Liu K, Feng Q, Hu ZY, Liu HZ, Fu GQ, Li YC, Zou RJ & Ny T 2004 Tissue-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1 are coordinately expressed during ovulation in the rhesus monkey. Endocrinology 145 1767-1775.
26. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV & Go AS 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 91 1357-1363.
27. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Di BS, Labella D, Russo T, Savastano S, Tolino A et al. 2004 Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reproductive Biomedicine Online 9 505-510.
28. Peng XR, Hsueh AJ & Ny T 1993 Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. European Journal of Biochemistry 214 147-156.
29. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH & Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology 51 581-586.
30. Risma KA, Clay CM, Nett TM, Wagner T, Yun J & Nilson JH 1995 Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. PNAS 92 1322-1326.
31. Sampson M, Kong C, Patel A, Unwin R & Jacobs HS 1996 Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clinical Endocrinology 45 623-629.
32. Sills ES, Drews CD, Perloe M, Tucker MJ, Kaplan CR & Palermo GD 2003 Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system. Gynecological Endocrinology 17 231-237.
33. DeTaeye B, Smith LH & Vaughan DE 2005 Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Current Opinion in Pharmacology 5 149-154.
34. Takahashi K, Eda Y, bu-Musa A, Okada S, Yoshino K & Kitao M 1994 Transvaginal ultrasound imaging, histopathology and endocrinopathy in patients with polycystic ovarian syndrome. Human Reproduction 9 1231-1236.
35. Tarkun I, Canturk Z, Arslan BC, Turemen E & Tarkun P 2004 The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal 51 467-472.
36. Vaughan DE 2005 PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis 3 1879-1883.
37. Wild S, Pierpoint T, McKeigue P & Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clinical Endocrinology 52 595-600.